In trading on Tuesday, shares of Corcept Therapeutics Inc (Symbol: CORT) crossed below their 200 day moving average of $73.97, changing hands as low as $69.91 per share. Corcept Therapeutics Inc ...

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 51.4% in the afternoon session after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting ...

Corcept Therapeutics is rated hold due to high binary risk from an imminent Teva lawsuit decision impacting Korlym sales. Exceptional Phase 3 data for relacorilant in platinum-resistant ovarian cancer ...

REDWOOD CITY, Calif., December 31, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat ...

(RTTNews) - Corcept Therapeutics Incorporated (CORT) shares fell 50.50%, trading at $34.74, down $35.45, after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and ...

Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' (CORT.O), opens new tab drug for the treatment of a rare hormonal disorder, the company said on ...

Investing.com -- Corcept Therapeutics Incorporated (NASDAQ:CORT) stock plunged 33.2% in premarket trading Wednesday after the company received a Complete Response Letter from the U.S. Food and Drug ...

A large exercise of company stock options by Joseph K Belanoff, Chief Executive Officer at Corcept Therapeutics (NASDAQ:CORT) was disclosed in a new SEC filing on December 29, as part of an insider ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

・Corcept had filed an NDA for relacorilant last year as a treatment for patients with hypercortisolism, which leads to a collection of symptoms known as Cushing’s Syndrome. ・The company said that this ...